Iterum Therapeutics PLC (ITRM) Peer Comparison

$0.06

$-0.02 (-23.92%)

As on 02-Jun-2026 09:30EDT

Market cap

$2 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.4

Div. Yield

0 %

Edit

	Iterum Therapeutics PLC (ITRM)	Alkermes (ALKS)	Prothena (PRTA)	GH Research PLC (GHRS)
Market cap ($ Mln)	2	7,954	479	1,918
Revenue ($ Mln)	0	1,668	55	--
Net Profit ($ Mln)	-26.96	66.12	-43.99	-62.27
Net Margin (%)	-6,913.08	3.97	-80.67	--
RoE (%)	--	3.65	-15.51	-19.48
Price to Earnings	--	128.14	--	--
Price-To-Book	0.43	4.54	1.62	5.47

Cashflow
Ratios

Cashflow ($ Mln)

	Iterum Therapeutics PLC (ITRM)	Alkermes (ALKS)	Prothena (PRTA)	GH Research PLC (GHRS)
Cash From Operating Activities	-26.77	439.12	-150.05	-42.29
Cash Flow from Investing Activities	18.21	-111.31	-0.30	65.14
Cash from Financing Activities	26.69	-494.14	1.55	-0.30
Net Cash Inflow / Outflow	--	--	--	--

Ratios

Profitability Ratios

	Iterum Therapeutics PLC (ITRM)	Alkermes (ALKS)	Prothena (PRTA)	GH Research PLC (GHRS)
ROCE (%)	-91.75	23.56	-22.84	-19.50
ROE (%)	472.61	27.52	-23.34	-19.58
ROA (%)	-73.30	17.51	-19.67	-18.80
EBIT Margin (%)	-6,253.08	--	--	--
Net Margin (%)	-6,913.08	23.57	-90.49	--
Cash Profit Margin (%)	-0.01	--	--	--

Growth Ratios

	Iterum Therapeutics PLC (ITRM)	Alkermes (ALKS)	Prothena (PRTA)	GH Research PLC (GHRS)
Revenue Growth (%)	-85.11	-0.06	0.48	--
EBIT Growth (%)	13.35	--	--	--
Net Profit Growth (%)	11.76	3.18	16.81	-9.48
EPS Growth (%)	58.25	0.05	0.17	-0.09
Book Value Growth (%)	71.93	--	--	--

Valuation Ratios

	Iterum Therapeutics PLC (ITRM)	Alkermes (ALKS)	Prothena (PRTA)	GH Research PLC (GHRS)
Price / Earnings	-1.41	13.05	-6.09	-9.35
Price / Book Value	-8.54	3.27	1.53	2.04
Dividend Yield (%)	--	--	--	--
EV/EBITDA	-2.59	8.31	-2.22	-5.58
Market Cap ($ Cr)	--	--	--	--

Solvency Ratios

	Iterum Therapeutics PLC (ITRM)	Alkermes (ALKS)	Prothena (PRTA)	GH Research PLC (GHRS)
Debt to Equity	-4.53	0.05	0.02	0.00
Short term debt to equity ratio	-0.04	0.00	0.01	0.00
Current Ratio	2.13	3.04	10.01	17.23
Quick Ratio	1.96	2.65	11.33	24.51
Interest Coverage	-10.61	20.65	--	-54.27

Operating Efficiency Ratios

	Iterum Therapeutics PLC (ITRM)	Alkermes (ALKS)	Prothena (PRTA)	GH Research PLC (GHRS)
Debtors to sales (%)	140.00	25.01	0.00	--
Asset Turnover	0.01	0.74	0.22	0.00
Receivable days	--	84.73	6.97	--
Inventory Days	--	274.90	-525.61	-206.40
Payable days	3,772.57	82.84	1,689.27	4,192.26
Cash Conversion Cycle	--	276.80	-2,207.91	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly